1
|
Single cell mutant selection for metabolic engineering of actinomycetes. Metab Eng 2022; 73:124-133. [PMID: 35809806 DOI: 10.1016/j.ymben.2022.07.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 05/31/2022] [Accepted: 07/01/2022] [Indexed: 11/23/2022]
Abstract
Actinomycetes are important producers of pharmaceuticals and industrial enzymes. However, wild type strains require laborious development prior to industrial usage. Here we present a generally applicable reporter-guided metabolic engineering tool based on random mutagenesis, selective pressure, and single-cell sorting. We developed fluorescence-activated cell sorting (FACS) methodology capable of reproducibly identifying high-performing individual cells from a mutant population directly from liquid cultures. Actinomycetes are an important source of catabolic enzymes, where product yields determine industrial viability. We demonstrate 5-fold yield improvement with an industrial cholesterol oxidase ChoD producer Streptomyces lavendulae to 20.4 U g-1 in three rounds. Strain development is traditionally followed by production medium optimization, which is a time-consuming multi-parameter problem that may require hard to source ingredients. Ultra-high throughput screening allowed us to circumvent medium optimization and we identified high ChoD yield production strains directly from mutant libraries grown under preset culture conditions. Genome-mining based drug discovery is a promising source of bioactive compounds, which is complicated by the observation that target metabolic pathways may be silent under laboratory conditions. We demonstrate our technology for drug discovery by activating a silent mutaxanthene metabolic pathway in Amycolatopsis. We apply the method for industrial strain development and increase mutaxanthene yields 9-fold to 99 mg l-1 in a second round of mutant selection. In summary, the ability to screen tens of millions of mutants in a single cell format offers broad applicability for metabolic engineering of actinomycetes for activation of silent metabolic pathways and to increase yields of proteins and natural products.
Collapse
|
2
|
Biocatalytic potential of basidiomycetes: Relevance, challenges and research interventions in industrial processes. SCIENTIFIC AFRICAN 2021. [DOI: 10.1016/j.sciaf.2021.e00717] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
3
|
Tian J, He Q, Oliveira C, Qian Y, Egan S, Xu J, Qian N, Langsdorf E, Warrack B, Aranibar N, Reily M, Borys M, Li ZJ. Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines. Eng Life Sci 2020; 20:112-125. [PMID: 32874175 PMCID: PMC7447880 DOI: 10.1002/elsc.201900124] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 09/27/2019] [Accepted: 11/13/2019] [Indexed: 01/17/2023] Open
Abstract
Increasing cell culture productivity of recombinant proteins via process improvements is the primary focus for research groups within biologics manufacturing. Any recommendations to improve a manufacturing process obviously must be effective, but also be robust, scalable, and with product quality comparable to the original process. In this study, we report that three different GS-/- CHO cell lines developed in media containing a standard concentration of the selection agent methionine sulfoximine (MSX), but then exposed to increased MSX concentrations during seed train expansion, achieved titer increases of 10-19%. This result was observed in processes already considerably optimized. Expanding the cells with a higher MSX concentration improved cell line production stability with increased culture age. Production cultures in 500-L and 1000-L bioreactors replicated laboratory results using 5-L bioreactors, demonstrating process robustness and scalability. Furthermore, product quality attributes of the final drug substance using the higher MSX process were comparable with those from cells expanded in media with the standard selection MSX concentration. Subsequent mechanistic investigations confirmed that the cells were not altered at the genetic level in terms of integration profiles or gene copy number, nor transcriptional levels of glutamine synthetase, heavy chain, or light chain genes. This study provides an effective and applicable strategy to improve the productivity of therapeutic proteins for biologics manufacturing.
Collapse
Affiliation(s)
- Jun Tian
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Qin He
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Christopher Oliveira
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Yueming Qian
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Susan Egan
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Jianlin Xu
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Nan‐Xin Qian
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Erik Langsdorf
- Molecular & Cellular ScienceBristol‐Myers Squibb CompanyPrincetonNJUSA
| | - Bethanne Warrack
- Drug Development and Preclinical StudiesBristol‐Myers Squibb CompanyPrincetonNJUSA
| | - Nelly Aranibar
- Drug Development and Preclinical StudiesBristol‐Myers Squibb CompanyPrincetonNJUSA
| | - Michael Reily
- Drug Development and Preclinical StudiesBristol‐Myers Squibb CompanyPrincetonNJUSA
| | - Michael Borys
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| | - Zheng Jian Li
- Biologics Process DevelopmentGlobal Product Development and Supply, Bristol‐Myers Squibb CompanyDevensMAUSA
| |
Collapse
|
4
|
O'Brien SA, Ojha J, Wu P, Hu WS. Multiplexed clonality verification of cell lines for protein biologic production. Biotechnol Prog 2020; 36:e2978. [PMID: 32034880 PMCID: PMC7803388 DOI: 10.1002/btpr.2978] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 12/11/2019] [Accepted: 02/05/2020] [Indexed: 12/11/2022]
Abstract
During the development of cell lines for therapeutic protein production, a vector harboring a product transgene is integrated into the genome. To ensure production stability and consistent product quality, single-cell cloning is then performed. Since cells derived from the same parental clone have the same transgene integration locus, the identity of the integration site can also be used to verify the clonality of a production cell line. In this study, we present a high-throughput pipeline for clonality verification through integration site analysis. Sequence capture of genomic fragments that contain both vector and host cell genome sequences was used followed by next-generation sequencing to sequence the relevant vector-genome junctions. A Python algorithm was then developed for integration site identification and validated using a cell line with known integration sites. Using this system, we identified the integration sites of the host vector for 31 clonal cell lines from five independent vector integration events while using one set of probes against common features of the host vector for transgene integration. Cell lines from the same lineage had common integration sites, and they were distinct from unrelated cell lines. The integration sites obtained for each clone as part of the analysis may also be used for clone selection, as the sites can have a profound effect on the transgene’s transcript level and the stability of the resulting cell line. This method thus provides a rapid system for integration site identification and clonality verification.
Collapse
Affiliation(s)
- Sofie A O'Brien
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| | - Juhi Ojha
- Pharmaceuticals Division, Biologics Development Department, Bayer HealthCare, Berkeley, California
| | - Paul Wu
- Pharmaceuticals Division, Biologics Development Department, Bayer HealthCare, Berkeley, California
| | - Wei-Shou Hu
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, Minnesota
| |
Collapse
|
5
|
Bandyopadhyay AA, O’Brien SA, Zhao L, Fu HY, Vishwanathan N, Hu WS. Recurring genomic structural variation leads to clonal instability and loss of productivity. Biotechnol Bioeng 2019; 116:41-53. [PMID: 30144379 PMCID: PMC7058117 DOI: 10.1002/bit.26823] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 07/13/2018] [Accepted: 08/23/2018] [Indexed: 12/31/2022]
Abstract
Chinese hamster ovary cells, commonly used in the production of therapeutic proteins, are aneuploid. Their chromosomes bear structural abnormality and undergo changes in structure and number during cell proliferation. Some production cell lines are unstable and lose their productivity over time in the manufacturing process and during the product's life cycle. To better understand the link between genomic structural changes and productivity stability, an immunoglobulin G producing cell line was successively single-cell cloned to obtain subclones that retained or lost productivity, and their genomic features were compared. Although each subclone started with a single karyotype, the progeny quickly diversified to a population with a distribution of chromosome numbers that is not distinctive from the parent and among subclones. The comparative genomic hybridization (CGH) analysis showed that the extent of copy variation of gene coding regions among different subclones stayed at levels of a few percent. Genome regions that were prone to loss of copies, including one with a product transgene integration site, were identified in CGH. The loss of the transgene copy was accompanied by loss of transgene transcript level. Sequence analysis of the host cell and parental producing cell showed prominent structural variations within the regions prone to loss of copies. Taken together, we demonstrated the transient nature of clonal homogeneity in cell line development and the retention of a population distribution of chromosome numbers; we further demonstrated that structural variation in the transgene integration region caused cell line instability. Future cell line development may target the transgene into structurally stable regions.
Collapse
Affiliation(s)
| | | | | | | | | | - Wei-Shou Hu
- Department of Chemical Engineering and Materials Science, University of Minnesota, 421 Washington Avenue SE, Minneapolis, MN 55455-0132 USA
| |
Collapse
|
6
|
O’Brien SA, Lee K, Fu HY, Lee Z, Le TS, Stach CS, McCann MG, Zhang AQ, Smanski MJ, Somia NV, Hu WS. Single Copy Transgene Integration in a Transcriptionally Active Site for Recombinant Protein Synthesis. Biotechnol J 2018; 13:e1800226. [PMID: 30024101 PMCID: PMC7058118 DOI: 10.1002/biot.201800226] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 07/09/2018] [Indexed: 12/21/2022]
Abstract
For the biomanufacturing of protein biologics, establishing stable cell lines with high transgene transcription is critical for high productivity. Modern genome engineering tools can direct transgene insertion to a specified genomic locus and can potentially become a valuable tool for cell line generation. In this study, the authors survey transgene integration sites and their transcriptional activity to identify characteristics of desirable regions. A lentivirus containing destabilized Green Fluorescent Protein (dGFP) is used to infect Chinese hamster ovary cells at a low multiplicity of infection, and cells with high or low GFP fluorescence are isolated. RNA sequencing and Assay for Transposase Accessible Chromatin using sequencing data shows integration sites with high GFP expression are in larger regions of high transcriptional activity and accessibility, but not necessarily within highly transcribed genes. This method is used to obtain high Immunoglobulin G (IgG) expressing cell lines with a single copy of the transgene integrated into transcriptionally active and accessible genomic regions. Dual recombinase-mediated cassette exchange is then employed to swap the IgG transgene for erythropoietin or tumor necrosis factor receptor-Fc. This work thus highlights a strategy to identify desirable sites for transgene integration and to streamline the development of new product producing cell lines.
Collapse
Affiliation(s)
- Sofie A. O’Brien
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Kyoungho Lee
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Hsu-Yuan Fu
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Zion Lee
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Tung S. Le
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Christopher S. Stach
- Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Meghan G. McCann
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Alicia Q. Zhang
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Michael J. Smanski
- Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Nikunj V. Somia
- Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN 55455-0132 USA
| | - Wei-Shou Hu
- Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455-0132 USA
| |
Collapse
|
7
|
Sevillano L, Díaz M, Santamaría RI. Development of an antibiotic marker-free platform for heterologous protein production in Streptomyces. Microb Cell Fact 2017; 16:164. [PMID: 28950904 PMCID: PMC5615484 DOI: 10.1186/s12934-017-0781-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Accepted: 09/20/2017] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND The industrial use of enzymes produced by microorganisms is continuously growing due to the need for sustainable solutions. Nevertheless, many of the plasmids used for recombinant production of proteins in bacteria are based on the use of antibiotic resistance genes as selection markers. The safety concerns and legal requirements surrounding the increased use of antibiotic resistance genes have made the development of new antibiotic-free approaches essential. RESULTS In this work, a system completely free of antibiotic resistance genes and useful for the production of high yields of proteins in Streptomyces is described. This system is based on the separation of the two components of the yefM/yoeBsl (antitoxin/toxin) operon; the toxin (yoeBsl) gene, responsible for host death, is integrated into the genome and the antitoxin gene (yefMsl), which inactivates the toxin, is located in the expression plasmid. To develop this system, the toxin gene was integrated into the genome of a strain lacking the complete operon, and the antibiotic resistance gene integrated along with the toxin was eliminated by Cre recombinase to generate a final host strain free of any antibiotic resistance marker. In the same way, the antibiotic resistance gene from the final expression plasmid was removed by Dre recombinase. The usefulness of this system was analysed by checking the production of two hydrolases from different Streptomyces. Production of both proteins, with potential industrial use, was high and stable over time after strain storage and after serial subcultures. These results support the robustness and stability of the positive selection system developed. CONCLUSIONS The total absence of antibiotic resistance genes makes this system a powerful tool for using Streptomyces as a host to produce proteins at the industrial level. This work is the first Streptomyces antibiotic marker-free system to be described. Graphical abstract Antibiotic marker-free platform for protein expression in Streptomyces. The antitoxin gene present in the expression plasmid counteracts the effect of the toxin gene in the genome. In absence of the expression plasmid, the toxin causes cell death ensuring that only plasmid-containing cells persist.
Collapse
Affiliation(s)
- Laura Sevillano
- Instituto de Biología Funcional y Genómica (IBFG), Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, C/Zacarías González no 2, 37007, Salamanca, Spain
| | - Margarita Díaz
- Instituto de Biología Funcional y Genómica (IBFG), Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, C/Zacarías González no 2, 37007, Salamanca, Spain.
| | - Ramón I Santamaría
- Instituto de Biología Funcional y Genómica (IBFG), Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, C/Zacarías González no 2, 37007, Salamanca, Spain.
| |
Collapse
|